XERS Key Statistics, Chart & Performance
The current stock price of XERS is 7.04 USD. In the past month the price decreased by -24.38%. In the past year, price increased by 114.63%.
XERS Latest News, Press Relases and Analysis
XERS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.67 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.85 | 496.24B | ||
| MRK | MERCK & CO. INC. | 11.4 | 250.78B | ||
| PFE | PFIZER INC | 7.88 | 143.39B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.28 | 97.21B | ||
| ZTS | ZOETIS INC | 19.38 | 54.45B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 23.18B | ||
| VTRS | VIATRIS INC | 4.54 | 12.32B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.05 | 11.47B | ||
| CORT | CORCEPT THERAPEUTICS INC | 88.31 | 8.17B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.75B |
Related stock screener links
About XERS
Company Profile
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 394 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
Company Info
XERIS BIOPHARMA HOLDINGS INC
1375 West Fulton Street, Suite 1300
Chicago ILLINOIS 60601 US
CEO: Paul R. Edick
Employees: 394
Phone: 18444455704
XERIS BIOPHARMA HOLDINGS INC / XERS FAQ
Can you describe the business of XERIS BIOPHARMA HOLDINGS INC?
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 394 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
What is the current price of XERS stock?
The current stock price of XERS is 7.04 USD. The price increased by 3.07% in the last trading session.
Does XERIS BIOPHARMA HOLDINGS INC pay dividends?
XERS does not pay a dividend.
What is the ChartMill technical and fundamental rating of XERS stock?
XERS has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is XERIS BIOPHARMA HOLDINGS INC (XERS) stock traded?
XERS stock is listed on the Nasdaq exchange.
Can you provide the market cap for XERIS BIOPHARMA HOLDINGS INC?
XERIS BIOPHARMA HOLDINGS INC (XERS) has a market capitalization of 1.14B USD. This makes XERS a Small Cap stock.
XERS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to XERS. When comparing the yearly performance of all stocks, XERS is one of the better performing stocks in the market, outperforming 94.37% of all stocks.
XERS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to XERS. XERS may be in some trouble as it scores bad on both profitability and health.
XERS Financial Highlights
Over the last trailing twelve months XERS reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 77.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.22% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
XERS Forecast & Estimates
12 analysts have analysed XERS and the average price target is 11.73 USD. This implies a price increase of 66.62% is expected in the next year compared to the current price of 7.04.
For the next year, analysts expect an EPS growth of 93.29% and a revenue growth 42.48% for XERS